Valeant Pharmaceuticals International Revenue and Competitors
Estimated Revenue & Valuation
- Valeant Pharmaceuticals International's estimated annual revenue is currently $446.1M per year.
- Valeant Pharmaceuticals International's estimated revenue per employee is $321,600
- Valeant Pharmaceuticals International's total funding is $1.2B.
Employee Data
- Valeant Pharmaceuticals International has 1387 Employees.
- Valeant Pharmaceuticals International grew their employee count by -3% last year.
Valeant Pharmaceuticals International's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman & CEO | Reveal Email/Phone |
2 | EVP/President, International | Reveal Email/Phone |
3 | VP and General Manager | Reveal Email/Phone |
4 | EVP /General Counsel | Reveal Email/Phone |
5 | SVP Diversified Products | Reveal Email/Phone |
6 | SVP Manfacturing/Supply Chain | Reveal Email/Phone |
7 | Director Process Excellence | Reveal Email/Phone |
8 | Quality Compliance Director EMEA | Reveal Email/Phone |
9 | Director, Corporate Audit Services | Reveal Email/Phone |
10 | Executive Director | Reveal Email/Phone |
Valeant Pharmaceuticals International Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $6.6M | 33 | 32% | N/A | N/A |
#2 | $38M | 189 | 6% | N/A | N/A |
#3 | $6.6M | 33 | 22% | N/A | N/A |
#4 | $4180M | 15242 | 1% | $550M | N/A |
#5 | $17.5M | 87 | 50% | N/A | N/A |
#6 | $6.7M | 125 | -37% | $199.6M | N/A |
#7 | $10.9M | 54 | 15% | N/A | N/A |
#8 | $15.3M | 76 | 33% | N/A | N/A |
#9 | $128.6M | 640 | 16% | N/A | N/A |
#10 | $18.7M | 93 | 21% | N/A | N/A |
What Is Valeant Pharmaceuticals International?
Valeant Pharmaceuticals International (NYSE: VRX) is a global, research-based, specialty pharmaceutical company that discovers, develops, manufactures and markets pharmaceutical products, primarily in the areas of neurology, dermatology and infectious disease. Valeant has made rapid strides under a new management team that laid out a strategic vision with a renewed focus on its specialty pharmaceuticals business, and has implemented major changes in the areas of product management, business development, research and development, corporate governance and supply chain operations.
keywords:N/A
$1.2B
Total Funding
1387
Number of Employees
$446.1M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Valeant Pharmaceuticals International News
... Astellas Pharma Inc. (Japan), Sanofi S.A. (France), Regeneron Pharmaceuticals, Inc. (U.S.), Valeant Pharmaceuticals International,.
In early 2015, he made an ill-fated bet on Valeant Pharmaceuticals International, which resulted in two years of double-digit portfolio...
Novartis; Allergan; Valeant Pharmaceuticals; Santen Pharmaceutical; Lupin Pharmaceuticals; Apotex; Akorn. Customization of the Report: This report can be...
Other Companies in Bridgewater
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $300M | 1591 | 8% | N/A |
#2 | $276.2M | 1895 | -2% | $68M |
#3 | $749.8M | 2186 | N/A | N/A |
#4 | $2070M | 5628 | 8% | $854M |
#5 | $1603.5M | 6363 | N/A | N/A |